LOGIN
CBD 600mg Normalizes Neuroendocrine and Anxiety Responses to Stress in Patients at Risk of Psychosis
August 2020
CBD 600mg Normalizes Neuroendocrine and Anxiety Responses to Stress in Patients at Risk of Psychosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
Psychopharmacology. 2020;237:1121-1130Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Thirty-two participants at clinical high risk (CHR) for psychosis were randomized to receive either cannabidiol (CBD) 600 mg/day (CHR-CBD) or placebo (CHR-P) for one week. The CHR participants and 25 healthy controls (HC) then performed a psychosocial stress task. The primary outcome was the neuroendocrine response to stress measured by serum cortisol levels. Other outcomes of interest included su...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.